US Stock Insider Trading | Royalty Pharma disclosed two insider transactions on February 25

K-LinePoet · 2026-03-13T13:40:42+00:00

Royalty Pharma disclosed multiple recent stock sales by executive Coyne Terrance P. on February 25, 2026, totaling approximately 200,000 shares and involving amounts exceeding $1,500,000. The company is a leading buyer of biopharmaceutical royalties and has been driving industry innovation continuously since 1996.

K-LinePoet

2026-03-13 13:40:42

Abstract generation in progress

On February 25, 2026, Royalty Pharma (RPRX) disclosed two insider trading transactions. Executive Coyne Terrance P. sold 32,900 shares on February 23, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 25, 2026	Executive	Coyne Terrance P.	February 23, 2026	Sell	32,900	45.32	1.5766 million
February 4, 2026	Executive	Coyne Terrance P.	February 3, 2026	Sell	108,800	42.84	4.6596 million
February 4, 2026	Executive	Coyne Terrance P.	February 2, 2026	Sell	108,400	42.08	4.5629 million
February 4, 2026	Executive	Coyne Terrance P.	February 3, 2026	Sell	6,195	42.84	265,400
February 4, 2026	Executive	Coyne Terrance P.	February 4, 2026	Sell	20,200	43.29	872,900
February 2, 2026	Executive	Urist Marshall	January 30, 2026	Sell	20,000	41.09	821,800
January 26, 2026	Executive	Urist Marshall	January 23, 2026	Sell	20,000	40.26	805,100
January 23, 2026	Executive	Coyne Terrance P.	January 20, 2026	Sell	69,600	39.35	2.7379 million
January 20, 2026	Executive	Urist Marshall	January 16, 2026	Sell	20,000	39.52	790,300
January 13, 2026	Executive	Urist Marshall	January 9, 2026	Sell	20,000	40.78	815,600

【Company Information】

Royalty Pharma plc was incorporated on February 6, 2020, under the laws of England and Wales. The company is the largest buyer of biopharmaceutical royalties and a major funder of innovation in the biopharmaceutical industry. Since its founding in 1996, it has been a pioneer in the royalty rights market, collaborating with innovators from academic institutions, research hospitals, and non-profit organizations (ranging from small and medium biotech firms to global pharmaceutical leaders). The company has accumulated a portfolio of royalties that entitle them to payments based on topline sales of many industry-leading therapies, including Imbruvica, Januvia, Kalydeco, Trikafta, Truvada, Tysabri, and Xtandi. The company funds innovation in the biopharmaceutical industry directly or indirectly—by co-funding late-stage clinical trials and new product launches in exchange for future royalties, or by acquiring existing royalties from original innovators—thus supporting industry innovation.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.